Biora Therapeutics’ (BIOR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Biora Therapeutics (NASDAQ:BIOR) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $15.00 target price on the stock. HC Wainwright also issued estimates for Biora Therapeutics’ Q3 2024 earnings at ($0.42) EPS, Q4 2024 earnings at ($0.43) EPS, FY2024 earnings at ($0.84) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($1.12) EPS and FY2028 earnings at ($0.96) EPS.

Biora Therapeutics Stock Down 1.0 %

NASDAQ:BIOR opened at $0.66 on Tuesday. The firm’s fifty day simple moving average is $0.67 and its 200 day simple moving average is $0.79. The stock has a market cap of $23.64 million, a P/E ratio of -0.09 and a beta of 1.23. Biora Therapeutics has a twelve month low of $0.48 and a twelve month high of $3.38.

Biora Therapeutics (NASDAQ:BIOR) last announced its earnings results on Wednesday, May 15th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16). The firm had revenue of $0.54 million for the quarter. On average, analysts expect that Biora Therapeutics will post -1.64 EPS for the current fiscal year.

About Biora Therapeutics

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.